Mutations in a gene called KRAS are one of the most common drivers of cancer, and they appear particularly frequently in pancreatic, lung, and colorectal cancers. Unfortunately, KRAS proteins were long considered “undruggable” due to their shape, but recently a drug that can latch onto them has been approved for phase 2 clinical trials. Read more . . .
Difficult to detect and with a low survival rate, pancreatic cancer is one of the most insidious forms of the disease. But now, researchers have identified an existing drug that could be repurposed to fight pancreatic cancer by targeting a key gene mutation.